Argenica Therapeutics

Argenica is developing and seeking to commercialise a “best in class” neuroprotective cationic arginine- rich peptide therapy to improve outcomes in stroke patients. Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover…More, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity.